900 related articles for article (PubMed ID: 12086760)
1. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
2. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
5. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
Chiasson JL
Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
[TBL] [Abstract][Full Text] [Related]
7. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
[TBL] [Abstract][Full Text] [Related]
8. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
[TBL] [Abstract][Full Text] [Related]
9. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR; Bethel MA; Chan JC; Chiasson JL; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L; Liyanage W; Schröder S; Tendera M; Theodorakis MJ; Tuomilehto J; Yang W; Hu D; Pan C;
Am Heart J; 2014 Jul; 168(1):23-9.e2. PubMed ID: 24952856
[TBL] [Abstract][Full Text] [Related]
10. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
11. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
12. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
Kawamori R; Tajima N; Iwamoto Y; Kashiwagi A; Shimamoto K; Kaku K;
Lancet; 2009 May; 373(9675):1607-14. PubMed ID: 19395079
[TBL] [Abstract][Full Text] [Related]
13. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
14. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
[TBL] [Abstract][Full Text] [Related]
15. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
16. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
17. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.
Andrulionytè L; Zacharova J; Chiasson JL; Laakso M;
Diabetologia; 2004 Dec; 47(12):2176-84. PubMed ID: 15592662
[TBL] [Abstract][Full Text] [Related]
18. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy.
Zeymer U; Schwarzmaier-D'assie A; Petzinna D; Chiasson JL;
Eur J Cardiovasc Prev Rehabil; 2004 Oct; 11(5):412-5. PubMed ID: 15616415
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance.
Pan CY; Gao Y; Chen JW; Luo BY; Fu ZZ; Lu JM; Guo XH; Cheng H
Diabetes Res Clin Pract; 2003 Sep; 61(3):183-90. PubMed ID: 12965108
[TBL] [Abstract][Full Text] [Related]
20. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial.
Lian F; Li G; Chen X; Wang X; Piao C; Wang J; Hong Y; Ba Z; Wu S; Zhou X; Lang J; Liu Y; Zhang R; Hao J; Zhu Z; Li H; Fang Liu H; Cao A; Yan Z; An Y; Bai Y; Wang Q; Zhen Z; Yu C; Wang CZ; Yuan CS; Tong X
J Clin Endocrinol Metab; 2014 Feb; 99(2):648-55. PubMed ID: 24432995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
